GRAL
GRAIL, Inc.87.02
-4.02-4.42%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.39BP/E (TTM)
-Basic EPS (TTM)
-10.66Dividend Yield
0%Recent Filings
8-K
8-K
GRAIL raises $325M
GRAIL, Inc. secured a $325 million private placement on October 18, 2025, issuing 4,639,543 shares at $70.05 each, closing October 21. This bolsters funding for commercial expansion and reimbursement, extending runway to 2030 alongside pending Samsung investments. Yet dilution looms for shareholders. Cash flows freely now.
8-K
Grail leases Sunnyvale HQ space
Grail inked a 11-year lease on September 11, 2025, for 75,556 square feet across three floors at 250 S. Mathilda Avenue, Sunnyvale, California, as its new headquarters, kicking off October 1, 2026, with initial monthly base rent of $449,558 escalating 5% annually, plus a $3.6 million letter of credit and $14.4 million tenant improvement allowance. This move signals Grail's commitment to expanding its life sciences footprint in Silicon Valley's biotech hub, yet the long lead time underscores relocation planning amid growth. No immediate financial strain evident.
10-Q
Q2 FY2025 results
Grail's Q2 revenue climbed 11% year-over-year to $35.5M, driven by a 22% jump in screening sales from higher Galleri test volume, though development services dipped 69% amid portfolio shifts. Gross margins held steady at 45% despite amortization pressures, while operating losses narrowed sharply to $158.9M from $1.6B, thanks to 51% cuts in R&D and 30% in sales & marketing after restructuring. Cash burn eased, with $602.8M in liquidity supporting runway through 2026; free cash flow turned positive at $84.5M (derived) on maturing securities. Yet net losses widened to $114.0M from a $28.0M IPR&D impairment tied to market changes. Litigation lingers from the Illumina spin-off.
8-K
Galleri revenue surges 21%
GRAIL reported Q2 2025 revenue of $35.5 million, up 11% year-over-year, driven by 21% U.S. Galleri growth to $34.2 million and 29% more tests sold at over 45,000. Net loss narrowed to $114.0 million, including $28.0 million impairment, while adjusted EBITDA improved 44% to $(78.3) million. PATHFINDER 2 trial showed stronger cancer detection and higher positive predictive value than prior studies. Detailed results head to ESMO 2025. Cash stands at $606.1 million.
BNR
Burning Rock Biotech Limited
18.74+2.98
CHEK
Check-Cap Ltd.
1.61+0.03
DGX
Quest Diagnostics Incorporated
178.66-5.45
EXAS
Exact Sciences Corporation
101.76+0.02
GH
Guardant Health, Inc.
100.00-2.67
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LUCD
Lucid Diagnostics Inc.
1.12+0.01
MYGN
Myriad Genetics, Inc.
6.88-0.11
PSNL
Personalis, Inc.
7.98-0.50
WGS
GeneDx Holdings Corp.
141.72-8.89